

PCT


NOTIFICATION CONCERNING
SUBMISSION OR TRANSMITTAL
OF PRIORITY DOCUMENT

(PCT Administrative Instructions, Section 411)

From the INTERNATIONAL BUREAU

To:

SHIGA, Masatake
OR Bldg.
23-3, Takadanobaba 3-chome
Shinjuku-ku
Tokyo 169-8925
JAPON



Date of mailing (day/month/year) 22 January 2001 (22.01.01)	
Applicant's or agent's file reference PC-8417	IMPORTANT NOTIFICATION
International application No. PCT/JP00/07694	International filing date (day/month/year) 01 November 2000 (01.11.00)
International publication date (day/month/year) Not yet published	Priority date (day/month/year) 01 November 1999 (01.11.99)
Applicant TAISHO PHARMACEUTICAL CO., LTD. et al	

1. The applicant is hereby notified of the date of receipt (except where the letters "NR" appear in the right-hand column) by the International Bureau of the priority document(s) relating to the earlier application(s) indicated below. Unless otherwise indicated by an asterisk appearing next to a date of receipt, or by the letters "NR", in the right-hand column, the priority document concerned was submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b).
2. This updates and replaces any previously issued notification concerning submission or transmittal of priority documents.
3. An asterisk(*) appearing next to a date of receipt, in the right-hand column, denotes a priority document submitted or transmitted to the International Bureau but not in compliance with Rule 17.1(a) or (b). In such a case, the attention of the applicant is directed to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.
4. The letters "NR" appearing in the right-hand column denote a priority document which was not received by the International Bureau or which the applicant did not request the receiving Office to prepare and transmit to the International Bureau, as provided by Rule 17.1(a) or (b), respectively. In such a case, the attention of the applicant is directed to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

<u>Priority date</u>	<u>Priority application No.</u>	<u>Country or regional Office or PCT receiving Office</u>	<u>Date of receipt of priority document</u>
01 Nove 1999 (01.11.99)	11/311137	JP	22 Dece 2000 (22.12.00)
28 Dece 1999 (28.12.99)	11/372347	JP	22 Dece 2000 (22.12.00)
15 June 2000 (15.06.00)	2000/180472	JP	22 Dece 2000 (22.12.00)
15 June 2000 (15.06.00)	2000/180473	JP	22 Dece 2000 (22.12.00)
15 June 2000 (15.06.00)	2000/180476	JP	22 Dece 2000 (22.12.00)
15 June 2000 (15.06.00)	2000/180478	JP	22 Dece 2000 (22.12.00)

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No. (41-22) 740.14.35

Authorized officer

Somsak Thiphrakesone

Telephone No. (41-22) 338.83.38

54
Translation

PATENT COOPERATION TREATY

PCT

09/869,103

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference PC-8417	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/JP00/07694	International filing date (day/month/year) 01 November 2000 (01.11.00)	Priority date (day/month/year) 01 November 1999 (01.11.99)
International Patent Classification (IPC) or national classification and IPC *SEE SUPPLEMENTAL SHEET		
Applicant TAISHO PHARMACEUTICAL CO., LTD.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of <u>4</u> sheets, including this cover sheet. <input checked="" type="checkbox"/> This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT). These annexes consist of a total of <u>14</u> sheets.
3. This report contains indications relating to the following items: I <input checked="" type="checkbox"/> Basis of the report II <input type="checkbox"/> Priority III <input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability IV <input type="checkbox"/> Lack of unity of invention V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement VI <input type="checkbox"/> Certain documents cited VII <input type="checkbox"/> Certain defects in the international application VIII <input type="checkbox"/> Certain observations on the international application

Date of submission of the demand 31 May 2001 (31.05.01)	Date of completion of this report 30 November 2001 (30.11.2001)
Name and mailing address of the IPEA/JP	Authorized officer
Facsimile No.	Telephone No.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/JP00/07694

I. Basis of the report

1. With regard to the **elements** of the international application:*

- ☐ the international application as originally filed
- ☒ the description:
pages 2-11, 13-16, 18, 20-22, 24-27, 29-32, 34-86, as originally filed
pages 1, 12, 12/1, 17, 19, 23, 28, 33, filed with the demand
pages _____, filed with the letter of _____
- ☒ the claims:
pages 1-4, 6, 7, 9-12, as originally filed
pages _____, as amended (together with any statement under Article 19
pages _____, filed with the demand
pages 5, 8, filed with the letter of 17 August 2001 (17.08.2001)
- ☐ the drawings:
pages _____, as originally filed
pages _____, filed with the demand
pages _____, filed with the letter of _____
- ☐ the sequence listing part of the description:
pages _____, as originally filed
pages _____, filed with the demand
pages _____, filed with the letter of _____

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language _____ which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. ☐ The amendments have resulted in the cancellation of:

- ☐ the description, pages _____
- ☐ the claims, Nos. _____
- ☐ the drawings, sheets/fig _____

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rule 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/JP 00/07694

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims	1-12	YES
	Claims		NO
Inventive step (IS)	Claims	1-12	YES
	Claims		NO
Industrial applicability (IA)	Claims	1-12	YES
	Claims		NO

2. Citations and explanations

Document 1: Koichi Hayakawa et al., "Quantitative structure-activity relations of fungicidal N-phenylformamidoximes", Journal of Pesticide Science, Vol. 17, No. 1 (1992), pp. 17-25

Document 2: JP, 53-132529, A (Hoechst AG), 18 November 1978 (18.11.78)

Document 3: EP, 132881, A1 (Nippon Soda Co., Ltd.), 13 February 1985 (13.02.85)

Document 4: Magdalena Alonso-Garcia et al., "Inhibition of 20-HETE production contributes to the vascular responses to nitric oxide", Hypertension, Vol. 29, No. 1, Pt. 2 (1997), pp. 320-325

Claims 1-12

Documents 1, 2 and 3 only disclose substances with a structure related to the substances described in Claims 1-12; they do not disclose or suggest an action in inhibiting production of 20-HETE.

Similarly, Document 4 discloses inhibition of 20-HETE production but does not disclose or suggest substances described in Claims 1-12.

Therefore, Claims 1-12 are novel and involve an inventive step.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/JP00/07694

Supplemental sheet of IPC

Continuation of IPC

A61K31/155, 31/245, 31/18, 31/275, 31/166, 31/502, 31/36,
31/4035, 31/42, 31/429, 31/505, 31/403, 31/416, 31/4192,
31/404, 31/4245, 31/415, 31/519, 31/428, 31/352, 31/4453,
31/40, 31/343, 31/433, 31/472, 31/47, 31/5375, 31/381, 31/44,
31/45, 31/505, 31/351, 31/341, 31/357, 31/426, 31/445,
31/4402, 31/522, C07C317/40, 323/41, 323/65, 323/12, 323/19,
C07C311/21, 311/46, 311/58, 259/14, C07D237/32, 317/66,
209/48, 261/14, 513/04, 239/46, 239/47, 209/94, 231/56,
249/18, 209/08, 271/10, 231/16, 495/04, 277/70, 277/44,
311/18, 239/42, 295/12, 231/12, 307/91, 209/82, 307/68,
277/64, 285/06, 217/12, 215/38, 239/26, 237/28, 215/22,
277/62, 295/08, 317/22, 215/14, 333/16, 307/42, 277/26,
213/30, 213/70, 319/06, 487/04, 207/27, 211/22, 307/12,
309/06, 307/40, 277/64, 473/08, A61P43/00, 13/12, 9/10, 9/00

国際調査報告

(法8条、法施行規則第40、41条)
〔PCT18条、PCT規則43、44〕

出願人又は代理人 の書類記号 PC-8417	今後の手続きについては、国際調査報告の送付通知様式(PCT/ISA/220) 及び下記5を参照すること。	
国際出願番号 PCT/JP00/07694	国際出願日 (日.月.年) 01.11.00	優先日 (日.月.年) 01.11.99
出願人(氏名又は名称) 大正製薬株式会社		

国際調査機関が作成したこの国際調査報告を法施行規則第41条(PCT18条)の規定に従い出願人に送付する。
この写しは国際事務局にも送付される。

この国際調査報告は、全部で 4 ページである。

☐ この調査報告に引用された先行技術文献の写しも添付されている。

1. 国際調査報告の基礎

a. 言語は、下記に示す場合を除くほか、この国際出願がされたものに基づき国際調査を行った。

☐ この国際調査機関に提出された国際出願の翻訳文に基づき国際調査を行った。

b. この国際出願は、ヌクレオチド又はアミノ酸配列を含んでおり、次の配列表に基づき国際調査を行った。

☐ この国際出願に含まれる書面による配列表

☐ この国際出願と共に提出されたフレキシブルディスクによる配列表

☐ 出願後に、この国際調査機関に提出された書面による配列表

☐ 出願後に、この国際調査機関に提出されたフレキシブルディスクによる配列表

☐ 出願後に提出した書面による配列表が出願時における国際出願の開示の範囲を超える事項を含まない旨の陳述書の提出があった。

☐ 書面による配列表に記載した配列とフレキシブルディスクによる配列表に記録した配列が同一である旨の陳述書の提出があった。

2. ☐ 請求の範囲の一部の調査ができない(第I欄参照)。

3. ☐ 発明の単一性が欠如している(第II欄参照)。

4. 発明の名称は ☒ 出願人が提出したものを承認する。
☐ 次に示すように国際調査機関が作成した。

5. 要約は ☒ 出願人が提出したものを承認する。

☐ 第III欄に示されているように、法施行規則第47条(PCT規則38.2(b))の規定により国際調査機関が作成した。出願人は、この国際調査報告の発送の日から1カ月以内にこの国際調査機関に意見を提出することができる。

6. 要約書とともに公表される図は、

第 _____ 図とする。 ☐ 出願人が示したとおりである。

☒ なし

☐ 出願人は図を示さなかった。

☐ 本図は発明の特徴を一層よく表している。

A. 発明の属する分野の分類 (国際特許分類 (IPC))

Int. Cl⁷ A61K31/155, 31/245, 31/18, 31/275, 31/166, 31/502, 31/36, 31/4035, 31/42, 31/429, 31/505, 31/403, 31/416, 31/4192, 31/404, 31/4245, 31/415, 31/519, 31/428, 31/352, 31/4453, 31/40, 31/343, 31/433, 31/472, 31/47, 31/5375, 31/381, 31/44, 31/45, 31/505, 31/351, 31/341, 31/357, 31/426, 31/445, 31/4402, 31/522, C07C317/40, 323/41, 323/65, 323/12, 323/19,

B. 調査を行った分野

調査を行った最小限資料 (国際特許分類 (IPC))

Int. Cl⁷ A61K31/155, 31/245, 31/18, 31/275, 31/166, 31/502, 31/36, 31/4035, 31/42, 31/429, 31/505, 31/403, 31/416, 31/4192, 31/404, 31/4245, 31/415, 31/519, 31/428, 31/352, 31/4453, 31/40, 31/343, 31/433, 31/472, 31/47, 31/5375, 31/381, 31/44, 31/45, 31/505, 31/351, 31/341, 31/357, 31/426, 31/445, 31/4402, 31/522, C07C317/40, 323/41, 323/65, 323/12, 323/19,

最小限資料以外の資料で調査を行った分野に含まれるもの

国際調査で使用した電子データベース (データベースの名称、調査に使用した用語)
REGISTRY (STN), CAPLUS (STN)

C. 関連すると認められる文献

引用文献の カテゴリー*	引用文献名 及び一部の箇所が関連するときは、その関連する箇所の表示	関連する 請求の範囲の番号
X A	Koichi HAYAKAWA et al. "Quantitative Structure-Activity Relationships of Fungicidal N-Phenylformamidoximes," Journal of Pesticide Science, Vol.17, No.1 (1992) pp.17-25 (p.23のTabel 3のNo.58)	5, 8 1-4, 6, 7, 9-12
A	J P, 53-132529, A (ヘキスト・アクテングゼルシャフト) 18. 11月. 1978 (18. 11. 78) & DE, 2717437, A & NL, 7804189, A & BE, 866194, A & FR, 2387946, A	1-12

☒ C欄の続きにも文献が列挙されている。

☐ パテントファミリーに関する別紙を参照。

* 引用文献のカテゴリー

「A」 特に関連のある文献ではなく、一般的技術水準を示すもの

「E」 国際出願日前の出願または特許であるが、国際出願日以後に公表されたもの

「L」 優先権主張に疑義を提起する文献又は他の文献の発行日若しくは他の特別な理由を確立するために引用する文献 (理由を付す)

「O」 口頭による開示、使用、展示等に言及する文献

「P」 国際出願日前で、かつ優先権の主張の基礎となる出願

の日の後に公表された文献

「T」 国際出願日又は優先日後に公表された文献であって出願と矛盾するものではなく、発明の原理又は理論の理解のために引用するもの

「X」 特に関連のある文献であって、当該文献のみで発明の新規性又は進歩性がないと考えられるもの

「Y」 特に関連のある文献であって、当該文献と他の1以上の文献との、当業者にとって自明である組合せによって進歩性がないと考えられるもの

「&」 同一パテントファミリー文献

国際調査を完了した日

16. 01. 01

国際調査報告の発送日

30.01.01

国際調査機関の名称及びあて先

日本国特許庁 (ISA/J P)

郵便番号100-8915

東京都千代田区霞が関三丁目4番3号

特許庁審査官 (権限のある職員)

今村 玲 英 子

印

4 C

8517

電話番号 03-3581-1101 内線 3452

C (続き) . 関連すると認められる文献		
引用文献の カテゴリー*	引用文献名 及び一部の箇所が関連するときは、その関連する箇所の表示	関連する 請求の範囲の番号
A	EP, 132881, A1 (NIPPON SODA CO., LTD.) 13. 2月. 1985 (13. 02. 85) & JP, 60-19759, A & AU, 8430229, A & SE, 8403711, A & DK, 8403469, A & FI, 8402861, A & ES, 542534, A	1-12
A	Magdalena Alonso-Galicia et al. "Inhibition of 20-HETE Production Contributes to the Vascular Responses to Nitric Oxide," Hypertension, Vol.29, No.1, Pt.2 (1997) pp.320-325	1-12

第2頁A欄 発明の属する分野の分類（国際特許分類（IPC））の続き

C07C311/21, 311/46, 311/58, 259/14, C07D237/32, 317/66, 209/48, 261/14, 513/04, 239/46, 239/47, 209/94, 231/56, 249/18, 209/08, 271/10, 231/16, 495/04, 277/70, 277/44, 311/18, 239/42, 295/12, 231/12, 307/91, 209/82, 307/68, 277/64, 285/06, 217/12, 215/38, 239/26, 237/28, 215/22, 277/62, 295/08, 317/22, 215/14, 333/16, 307/42, 277/26, 213/30, 213/70, 319/06, 487/04, 207/27, 211/22, 307/12, 309/06, 307/40, 277/64, 473/08, A61P43/00, 13/12, 9/10, 9/00

第2頁B欄 調査を行った分野 調査を行った最小限資料（国際特許分類（IPC））の続き

C07C311/21, 311/46, 311/58, 259/14, C07D237/32, 317/66, 209/48, 261/14, 513/04, 239/46, 239/47, 209/94, 231/56, 249/18, 209/08, 271/10, 231/16, 495/04, 277/70, 277/44, 311/18, 239/42, 295/12, 231/12, 307/91, 209/82, 307/68, 277/64, 285/06, 217/12, 215/38, 239/26, 237/28, 215/22, 277/62, 295/08, 317/22, 215/14, 333/16, 307/42, 277/26, 213/30, 213/70, 319/06, 487/04, 207/27, 211/22, 307/12, 309/06, 307/40, 277/64, 473/08, A61P43/00, 13/12, 9/10, 9/00